img

Global Nucleic Acid Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global Nucleic Acid Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Due to the COVID-19 pandemic, the global Nucleic Acid Drugs market size was US$ million in 2023 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the forecast period 2023-2033. Fully considering the economic change by this health crisis, Antisense Nucleic Acid Drugs accounting for % of the Nucleic Acid Drugs global market in 2023, is projected to value US$ million by 2033, growing at a revised % CAGR from 2023 to 2033. While Genetic Disease segment is altered to an % CAGR throughout this forecast period.
The global key companies of Nucleic Acid Drugs include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Mina Therapeutics, BioNTech, NeXstar Pharmaceuticals, Nippon Shinyaku, Moderna Therapeutics and CureVac, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
The United States Nucleic Acid Drugs market size was US$ million in 2023, while China size was US$ million. The proportion of the United States was % in 2023, while China percentage was %, and it is predicted that China share will reach % in 2033, trailing a CAGR of % through the analysis period. As for the Europe Nucleic Acid Drugs landscape, Germany is projected to reach US$ million by 2033. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Nucleic Acid Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Nucleic Acid Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Nucleic Acid Drugs market. Readers of the report can become informed about current and future trends of the global Nucleic Acid Drugs market and how they will impact market growth during the forecast period.



By Company


Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Mina Therapeutics
BioNTech
NeXstar Pharmaceuticals
Nippon Shinyaku
Moderna Therapeutics
CureVac
Regulus Therapeutics
Miragen Therapeutics
Segment by Type
Antisense Nucleic Acid Drugs
siRNA Drugs
saRNA Drugs
miRNA Drugs
mRNA Drugs
other

Segment by Application


Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Nucleic Acid Drugs in global and regional level.
Chapter 3Detailed analysis of Nucleic Acid Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid Drugs revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid Drugs Market Size Growth Rate by Type: 2018 VS 2023 VS 2033
1.2.2 Antisense Nucleic Acid Drugs
1.2.3 siRNA Drugs
1.2.4 saRNA Drugs
1.2.5 miRNA Drugs
1.2.6 mRNA Drugs
1.2.7 other
1.3 Market by Application
1.3.1 Global Nucleic Acid Drugs Market Growth Rate by Application: 2018 VS 2023 VS 2033
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Nucleic Acid Drugs Market Size (2018-2033)
2.2 Nucleic Acid Drugs Market Size across Key Geographies Worldwide: 2018 VS 2023 VS 2033
2.3 Global Nucleic Acid Drugs Market Size by Region (2018-2023)
2.4 Global Nucleic Acid Drugs Market Size Forecast by Region (2024-2033)
2.5 Global Top 10 Nucleic Acid Drugs Countries Ranking by Market Size
3 Nucleic Acid Drugs Competitive by Company
3.1 Global Nucleic Acid Drugs Revenue by Players
3.1.1 Global Nucleic Acid Drugs Revenue by Players (2018-2023)
3.1.2 Global Nucleic Acid Drugs Market Share by Players (2018-2023)
3.2 Global Nucleic Acid Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Nucleic Acid Drugs Revenue
3.4 Global Nucleic Acid Drugs Market Concentration Ratio
3.4.1 Global Nucleic Acid Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Drugs Revenue in 2023
3.5 Global Key Players of Nucleic Acid Drugs Head office and Area Served
3.6 Global Key Players of Nucleic Acid Drugs, Product and Application
3.7 Global Key Players of Nucleic Acid Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Nucleic Acid Drugs Breakdown Data by Type
4.1 Global Nucleic Acid Drugs Historic Revenue by Type (2018-2023)
4.2 Global Nucleic Acid Drugs Forecasted Revenue by Type (2024-2033)
5 Global Nucleic Acid Drugs Breakdown Data by Application
5.1 Global Nucleic Acid Drugs Historic Market Size by Application (2018-2023)
5.2 Global Nucleic Acid Drugs Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Nucleic Acid Drugs Revenue by Company (2021-2023)
6.2 North America Nucleic Acid Drugs Revenue by Type (2018-2033)
6.3 North America Nucleic Acid Drugs Revenue by Application (2018-2033)
6.4 North America Nucleic Acid Drugs Revenue by Country (2018-2033)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Nucleic Acid Drugs Revenue by Company (2021-2023)
7.2 Europe Nucleic Acid Drugs Revenue by Type (2018-2033)
7.3 Europe Nucleic Acid Drugs Revenue by Application (2018-2033)
7.4 Europe Nucleic Acid Drugs Revenue by Country (2018-2033)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Nucleic Acid Drugs Revenue by Company (2021-2023)
8.2 Asia Pacific Nucleic Acid Drugs Revenue by Type (2018-2033)
8.3 Asia Pacific Nucleic Acid Drugs Revenue by Application (2018-2033)
8.4 Asia Pacific Nucleic Acid Drugs Revenue by Region (2018-2033)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Nucleic Acid Drugs Revenue by Company (2021-2023)
9.2 Latin America Nucleic Acid Drugs Revenue by Type (2018-2033)
9.3 Latin America Nucleic Acid Drugs Revenue by Application (2018-2033)
9.4 Latin America Nucleic Acid Drugs Revenue by Country (2018-2033)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Nucleic Acid Drugs Revenue by Company (2021-2023)
10.2 Middle East and Africa Nucleic Acid Drugs Revenue by Type (2018-2033)
10.3 Middle East and Africa Nucleic Acid Drugs Revenue by Application (2018-2033)
10.4 Middle East and Africa Nucleic Acid Drugs Revenue by Country (2018-2033)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Nucleic Acid Drugs Products and Services
11.1.4 Sarepta Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.1.5 Sarepta Therapeutics Nucleic Acid Drugs SWOT Analysis
11.1.6 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Products and Services
11.2.4 Ionis Pharmaceuticals Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.2.5 Ionis Pharmaceuticals Nucleic Acid Drugs SWOT Analysis
11.2.6 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Details
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Nucleic Acid Drugs Products and Services
11.3.4 Alnylam Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.3.5 Alnylam Nucleic Acid Drugs SWOT Analysis
11.3.6 Alnylam Recent Development
11.4 Mina Therapeutics
11.4.1 Mina Therapeutics Company Details
11.4.2 Mina Therapeutics Business Overview
11.4.3 Mina Therapeutics Nucleic Acid Drugs Products and Services
11.4.4 Mina Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.4.5 Mina Therapeutics Nucleic Acid Drugs SWOT Analysis
11.4.6 Mina Therapeutics Recent Development
11.5 BioNTech
11.5.1 BioNTech Company Details
11.5.2 BioNTech Business Overview
11.5.3 BioNTech Nucleic Acid Drugs Products and Services
11.5.4 BioNTech Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.5.5 BioNTech Nucleic Acid Drugs SWOT Analysis
11.5.6 BioNTech Recent Development
11.6 NeXstar Pharmaceuticals
11.6.1 NeXstar Pharmaceuticals Company Details
11.6.2 NeXstar Pharmaceuticals Business Overview
11.6.3 NeXstar Pharmaceuticals Nucleic Acid Drugs Products and Services
11.6.4 NeXstar Pharmaceuticals Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.6.5 NeXstar Pharmaceuticals Nucleic Acid Drugs SWOT Analysis
11.6.6 NeXstar Pharmaceuticals Recent Development
11.7 Nippon Shinyaku
11.7.1 Nippon Shinyaku Company Details
11.7.2 Nippon Shinyaku Business Overview
11.7.3 Nippon Shinyaku Nucleic Acid Drugs Products and Services
11.7.4 Nippon Shinyaku Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.7.5 Nippon Shinyaku Nucleic Acid Drugs SWOT Analysis
11.7.6 Nippon Shinyaku Recent Development
11.8 Moderna Therapeutics
11.8.1 Moderna Therapeutics Company Details
11.8.2 Moderna Therapeutics Business Overview
11.8.3 Moderna Therapeutics Nucleic Acid Drugs Products and Services
11.8.4 Moderna Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.8.5 Moderna Therapeutics Nucleic Acid Drugs SWOT Analysis
11.8.6 Moderna Therapeutics Recent Development
11.9 CureVac
11.9.1 CureVac Company Details
11.9.2 CureVac Business Overview
11.9.3 CureVac Nucleic Acid Drugs Products and Services
11.9.4 CureVac Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.9.5 CureVac Nucleic Acid Drugs SWOT Analysis
11.9.6 CureVac Recent Development
11.10 Regulus Therapeutics
11.10.1 Regulus Therapeutics Company Details
11.10.2 Regulus Therapeutics Business Overview
11.10.3 Regulus Therapeutics Nucleic Acid Drugs Products and Services
11.10.4 Regulus Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.10.5 Regulus Therapeutics Nucleic Acid Drugs SWOT Analysis
11.10.6 Regulus Therapeutics Recent Development
11.11 Miragen Therapeutics
11.11.1 Miragen Therapeutics Company Details
11.11.2 Miragen Therapeutics Business Overview
11.11.3 Miragen Therapeutics Nucleic Acid Drugs Products and Services
11.11.4 Miragen Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023)
11.11.5 Miragen Therapeutics Recent Development
12 Nucleic Acid Drugs Market Dynamics
12.1 Nucleic Acid Drugs Industry Trends
12.2 Nucleic Acid Drugs Market Drivers
12.3 Nucleic Acid Drugs Market Challenges
12.4 Nucleic Acid Drugs Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Nucleic Acid Drugs Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2023 VS 2033
Table 2. Key Players of Antisense Nucleic Acid Drugs
Table 3. Key Players of siRNA Drugs
Table 4. Key Players of saRNA Drugs
Table 5. Key Players of miRNA Drugs
Table 6. Key Players of mRNA Drugs
Table 7. Key Players of other
Table 8. Global Nucleic Acid Drugs Market Size Growth Rate by Application (US$ Million), 2018 VS 2023 VS 2033
Table 9. Global Nucleic Acid Drugs Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2023 VS 2033
Table 10. Global Nucleic Acid Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 11. Global Nucleic Acid Drugs Revenue Forecast by Region (2024-2033) & (US$ Million)
Table 12. Global Nucleic Acid Drugs Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Table 13. Global Nucleic Acid Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 14. Global Nucleic Acid Drugs Market Share by Players (2018-2023)
Table 15. Global Top Nucleic Acid Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid Drugs as of 2023)
Table 16. Ranking of Global Top Nucleic Acid Drugs Companies by Revenue (US$ Million) in 2023
Table 17. Global 5 Largest Players Market Share by Nucleic Acid Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 18. Global Key Players of Nucleic Acid Drugs, Headquarters and Area Served
Table 19. Global Key Players of Nucleic Acid Drugs, Product and Application
Table 20. Global Key Players of Nucleic Acid Drugs, Date of Enter into This Industry
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Nucleic Acid Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 23. Global Nucleic Acid Drugs Revenue Market Share by Type (2018-2023)
Table 24. Global Nucleic Acid Drugs Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 25. Global Nucleic Acid Drugs Revenue Market Share by Type (2024-2033)
Table 26. Global Nucleic Acid Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 27. Global Nucleic Acid Drugs Revenue Market Share by Application (2018-2023)
Table 28. Global Nucleic Acid Drugs Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 29. Global Nucleic Acid Drugs Revenue Market Share by Application (2024-2033)
Table 30. North America Nucleic Acid Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 31. North America Nucleic Acid Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 32. North America Nucleic Acid Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 33. North America Nucleic Acid Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 34. North America Nucleic Acid Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 35. North America Nucleic Acid Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 36. North America Nucleic Acid Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 37. North America Nucleic Acid Drugs Revenue by Country (2024-2033) & (US$ Million)
Table 38. Europe Nucleic Acid Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 39. Europe Nucleic Acid Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 40. Europe Nucleic Acid Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 41. Europe Nucleic Acid Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 42. Europe Nucleic Acid Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 43. Europe Nucleic Acid Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 44. Europe Nucleic Acid Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 45. Europe Nucleic Acid Drugs Revenue by Country (2024-2033) & (US$ Million)
Table 46. Asia Pacific Nucleic Acid Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 47. Asia Pacific Nucleic Acid Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 48. Asia Pacific Nucleic Acid Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 49. Asia Pacific Nucleic Acid Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 50. Asia Pacific Nucleic Acid Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 51. Asia-Pacific Nucleic Acid Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 52. Asia Pacific Nucleic Acid Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 53. Asia Pacific Nucleic Acid Drugs Revenue by Region (2024-2033) & (US$ Million)
Table 54. Latin America Nucleic Acid Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 55. Latin America Nucleic Acid Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 56. Latin America Nucleic Acid Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 57. Latin America Nucleic Acid Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 58. Latin America Nucleic Acid Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 59. Latin America Nucleic Acid Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 60. Latin America Nucleic Acid Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 61. Latin America Nucleic Acid Drugs Revenue by Country (2024-2033) & (US$ Million)
Table 62. Middle East and Africa Nucleic Acid Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 63. Middle East and Africa Nucleic Acid Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 64. Middle East and Africa Nucleic Acid Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 65. Middle East and Africa Nucleic Acid Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 66. Middle East and Africa Nucleic Acid Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 67. Middle East and Africa Nucleic Acid Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 68. Middle East and Africa Nucleic Acid Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 69. Middle East and Africa Nucleic Acid Drugs Revenue by Country (2024-2033) & (US$ Million)
Table 70. Sarepta Therapeutics Company Details
Table 71. Sarepta Therapeutics Business Overview
Table 72. Sarepta Therapeutics Nucleic Acid Drugs Product and Services
Table 73. Sarepta Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 74. Sarepta Therapeutics Nucleic Acid Drugs SWOT Analysis
Table 75. Sarepta Therapeutics Recent Development
Table 76. Ionis Pharmaceuticals Company Details
Table 77. Ionis Pharmaceuticals Business Overview
Table 78. Ionis Pharmaceuticals Nucleic Acid Drugs Product and Services
Table 79. Ionis Pharmaceuticals Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 80. Ionis Pharmaceuticals Nucleic Acid Drugs SWOT Analysis
Table 81. Ionis Pharmaceuticals Recent Development
Table 82. Alnylam Company Details
Table 83. Alnylam Business Overview
Table 84. Alnylam Nucleic Acid Drugs Product and Services
Table 85. Alnylam Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 86. Alnylam Nucleic Acid Drugs SWOT Analysis
Table 87. Alnylam Recent Development
Table 88. Mina Therapeutics Company Details
Table 89. Mina Therapeutics Business Overview
Table 90. Mina Therapeutics Nucleic Acid Drugs Product and Services
Table 91. Mina Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 92. Mina Therapeutics Nucleic Acid Drugs SWOT Analysis
Table 93. Mina Therapeutics Recent Development
Table 94. BioNTech Company Details
Table 95. BioNTech Business Overview
Table 96. BioNTech Nucleic Acid Drugs Product and Services
Table 97. BioNTech Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 98. BioNTech Nucleic Acid Drugs SWOT Analysis
Table 99. BioNTech Recent Development
Table 100. NeXstar Pharmaceuticals Company Details
Table 101. NeXstar Pharmaceuticals Business Overview
Table 102. NeXstar Pharmaceuticals Nucleic Acid Drugs Product and Services
Table 103. NeXstar Pharmaceuticals Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 104. NeXstar Pharmaceuticals Nucleic Acid Drugs SWOT Analysis
Table 105. NeXstar Pharmaceuticals Recent Development
Table 106. Nippon Shinyaku Company Details
Table 107. Nippon Shinyaku Business Overview
Table 108. Nippon Shinyaku Nucleic Acid Drugs Product and Services
Table 109. Nippon Shinyaku Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 110. Nippon Shinyaku Nucleic Acid Drugs SWOT Analysis
Table 111. Nippon Shinyaku Recent Development
Table 112. Moderna Therapeutics Company Details
Table 113. Moderna Therapeutics Business Overview
Table 114. Moderna Therapeutics Nucleic Acid Drugs Product and Services
Table 115. Moderna Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 116. Moderna Therapeutics Nucleic Acid Drugs SWOT Analysis
Table 117. Moderna Therapeutics Recent Development
Table 118. CureVac Company Details
Table 119. CureVac Business Overview
Table 120. CureVac Nucleic Acid Drugs Product and Services
Table 121. CureVac Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 122. CureVac Nucleic Acid Drugs SWOT Analysis
Table 123. CureVac Recent Development
Table 124. Regulus Therapeutics Company Details
Table 125. Regulus Therapeutics Business Overview
Table 126. Regulus Therapeutics Nucleic Acid Drugs Product and Services
Table 127. Regulus Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 128. Regulus Therapeutics Nucleic Acid Drugs SWOT Analysis
Table 129. Regulus Therapeutics Recent Development
Table 130. Miragen Therapeutics Company Details
Table 131. Miragen Therapeutics Business Overview
Table 132. Miragen Therapeutics Nucleic Acid Drugs Product and Services
Table 133. Miragen Therapeutics Nucleic Acid Drugs Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
Table 134. Miragen Therapeutics Recent Development
Table 135. Nucleic Acid Drugs Market Trends
Table 136. Nucleic Acid Drugs Market Drivers
Table 137. Nucleic Acid Drugs Market Challenges
Table 138. Nucleic Acid Drugs Market Restraints
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Nucleic Acid Drugs Product Picture
Figure 2. Global Nucleic Acid Drugs Market Size by Type (US$ Million): 2018 VS 2023 VS 2033
Figure 3. Global Nucleic Acid Drugs Market Share by Type: 2023 VS 2033
Figure 4. Antisense Nucleic Acid Drugs Features
Figure 5. siRNA Drugs Features
Figure 6. saRNA Drugs Features
Figure 7. miRNA Drugs Features
Figure 8. mRNA Drugs Features
Figure 9. other Features
Figure 10. Global Nucleic Acid Drugs Market Size by Application (US$ Million): 2018 VS 2023 VS 2033
Figure 11. Global Nucleic Acid Drugs Market Share by Application: 2023 VS 2033
Figure 12. Genetic Disease
Figure 13. Cancer
Figure 14. Cardiovascular Diseases
Figure 15. Other
Figure 16. Nucleic Acid Drugs Report Years Considered
Figure 17. Global Nucleic Acid Drugs Revenue, (US$ Million), 2018 VS 2023 VS 2033
Figure 18. Global Nucleic Acid Drugs Market Size 2018-2033 (US$ Million)
Figure 19. Global Nucleic Acid Drugs Market Size Market Share by Region: 2023 VS 2033
Figure 20. Global Nucleic Acid Drugs Revenue Market Share by Region in 2018 VS 2023
Figure 21. Global Nucleic Acid Drugs Revenue Market Share Forecast by Region (2024-2033)
Figure 22. Global Top 10 Nucleic Acid Drugs Countries Ranking by Market Size (US$ Million) in 2023
Figure 23. Global Nucleic Acid Drugs Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Figure 24. Global Nucleic Acid Drugs Market Share by Players in 2023
Figure 25. Global Top Nucleic Acid Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid Drugs as of 2023)
Figure 26. The Top 10 and 5 Players Market Share by Nucleic Acid Drugs Revenue in 2023
Figure 27. North America Nucleic Acid Drugs Revenue Market Share by Company in 2023
Figure 28. North America Nucleic Acid Drugs Revenue Market Share by Type (2018-2033)
Figure 29. North America Nucleic Acid Drugs Revenue Market Share by Application (2018-2033)
Figure 30. North America Nucleic Acid Drugs Revenue Share by Country (2018-2033)
Figure 31. U.S. Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 32. Canada Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 33. Europe Nucleic Acid Drugs Revenue Market Share by Company in 2023
Figure 34. Europe Nucleic Acid Drugs Revenue Market Share by Type (2018-2033)
Figure 35. Europe Nucleic Acid Drugs Revenue Market Share by Application (2018-2033)
Figure 36. Europe Nucleic Acid Drugs Revenue Share by Country (2018-2033)
Figure 37. Germany Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 38. France Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 39. U.K. Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 40. Italy Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 41. Russia Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 42. Asia Pacific Nucleic Acid Drugs Revenue Market Share by Company in 2023
Figure 43. Asia Pacific Nucleic Acid Drugs Revenue Market Share by Type (2018-2033)
Figure 44. Asia Pacific Nucleic Acid Drugs Revenue Market Share by Application (2018-2033)
Figure 45. Asia Pacific Nucleic Acid Drugs Revenue Share by Region (2018-2033)
Figure 46. China Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 47. Japan Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 48. South Korea Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 49. India Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 50. Australia Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 51. Taiwan Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 52. Indonesia Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 53. Thailand Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 54. Malaysia Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 55. Philippines Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 56. Vietnam Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 57. Latin America Nucleic Acid Drugs Revenue Market Share by Company in 2023
Figure 58. Latin America Nucleic Acid Drugs Revenue Market Share by Type (2018-2033)
Figure 59. Latin America Nucleic Acid Drugs Revenue Market Share by Application (2018-2033)
Figure 60. Latin America Nucleic Acid Drugs Revenue Share by Country (2018-2033)
Figure 61. Mexico Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 62. Brazil Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 63. Argentina Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 64. Middle East and Africa Nucleic Acid Drugs Revenue Market Share by Company in 2023
Figure 65. Middle East and Africa Nucleic Acid Drugs Revenue Market Share by Type (2018-2033)
Figure 66. Middle East and Africa Nucleic Acid Drugs Revenue Market Share by Application (2018-2033)
Figure 67. Middle East and Africa Nucleic Acid Drugs Revenue Share by Country (2018-2033)
Figure 68. Turkey Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 69. Saudi Arabia Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 70. U.A.E Nucleic Acid Drugs Revenue (2018-2033) & (US$ Million)
Figure 71. Sarepta Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 72. Ionis Pharmaceuticals Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 73. Alnylam Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 74. Mina Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 75. BioNTech Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 76. NeXstar Pharmaceuticals Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 77. Nippon Shinyaku Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 78. Moderna Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 79. CureVac Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 80. Regulus Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 81. Miragen Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2018-2023)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed